Sironax

About Sironax

Sironax is an emerging leader in the discovery and development of transformational therapies that address the root causes of age-related degenerative diseases. The company tackles aging issue at its dual pillars of mental decline (neurodegeneration) and physical decline (muscular and metabolic disorders) by targeting three core drivers: dysregulated cell death, uncontrolled inflammation, and disrupted energy homeostasis. To date, Sironax's breakthrough pipeline contains multiple first-in-class and/or potentially best-in-class programs, among which 3 have entered into clinical stage. Each of these programs demonstrates Sironax’s unique biological insights and mechanistic innovations, with research focus spanning neuroinflammation, axonal degeneration, muscular weakness, epithelial cell death, and metabolic disorders. All these clinical assets at Sironax are de novo designed and synthesized within the company, each of which features distinct chemical scaffold. In parallel to the actively ongoing clinical development, the company also continues to expand its discovery footprint and plan to advance additional programs into clinic over the next few years. With operations in the U.S., China, Australia and soon Europe, Sironax presently has 140+ employees and growing. We continue to build our global team of highly skilled chemists, biologists, and clinicians. Along with decades of experience in global pharmaceutical R&D, our team shares a collective vision of shifting the treatment paradigm for age-related degenerative disease to ultimately improve the lives of millions of patients and their families around the world.